Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00787761 · OUTCOME

Overall Survival (OS) at 24 Months

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer · Source last updated 2012-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
24 months

What was measured

Overall survival refers to the length of time a patient is alive after transplant regardless of whether they have progressive or relapsed disease.

Analysis population: 23 patients were able to be analyzed for OS at 24 months

Groups in this outcome

RIC Transplant Using ATG, Busulfan, Fludarabine and Cytoxan

All patients received ATG 1mg/kg Day-16 and then 3.5 mg/kg Day -15 Fludarabine 30mg/m2/day on days -7 to -3 Busulfan 130 mg/m2 on days -4 \& -3 Cyclophosphamide 1.5 g/m2 on day -2 Tacrolimus begins 0.03mg/kg bid on Day -1 Stem Cell transplant on Day 0 Methotrexate 5mg/m2 given D+1, +3 and +6

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RIC Transplant Using ATG, Busulfan, Fludarabine and Cytoxan23

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
RIC Transplant Using ATG, Busulfan, Fludarabine and Cytoxan16Not reported4383Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        43
        upper Limit
        83
        value
        16
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Overall survival refers to the length of time a patient is alive after transplant regardless of whether they have progressive or relapsed disease.
groups
  1. description
    All patients received ATG 1mg/kg Day-16 and then 3.5 mg/kg Day -15 Fludarabine 30mg/m2/day on days -7 to -3 Busulfan 130 mg/m2 on days -4 \& -3 Cyclophosphamide 1.5 g/m2 on day -2 Tacrolimus begins 0.03mg/kg bid on Day -1 Stem Cell transplant on Day 0 Methotrexate 5mg/m2 given D+1, +3 and +6
    id
    OG000
    title
    RIC Transplant Using ATG, Busulfan, Fludarabine and Cytoxan
param Type
NUMBER
population Description
23 patients were able to be analyzed for OS at 24 months
reporting Status
POSTED
time Frame
24 months
title
Overall Survival (OS) at 24 Months
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice